A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Identifieur interne : 001270 ( Main/Exploration ); précédent : 001269; suivant : 001271A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Auteurs : M. Martín [Espagne] ; A. Chan [Australie] ; L. Dirix [Belgique] ; J. O'Shaughnessy [États-Unis] ; R. Hegg [Brésil] ; A. Manikhas [Russie] ; M. Shtivelband [États-Unis] ; P. Krivorotko [Russie] ; N. Batista L Pez [Espagne] ; M. Campone [France] ; M. Ruiz Borrego [Espagne] ; Q J Khan ; J T Beck [États-Unis] ; M. Ramos Vázquez [Espagne] ; P. Urban [Suisse] ; S. Goteti ; E. Di Tomaso [États-Unis] ; C. Massacesi [France] ; S. Delaloge [France]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120) appear synergistic with paclitaxel in preclinical and clinical models.
DOI: 10.1093/annonc/mdw562
PubMed: 27803006
Affiliations:
- Australie, Belgique, Brésil, Espagne, France, Russie, Suisse, États-Unis
- Communauté de Madrid, Texas, Île-de-France
- Dallas, Madrid, Paris
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001112
- to stream PubMed, to step Curation: 001109
- to stream PubMed, to step Checkpoint: 001109
- to stream Ncbi, to step Merge: 003E10
- to stream Ncbi, to step Curation: 003E10
- to stream Ncbi, to step Checkpoint: 003E10
- to stream Main, to step Merge: 001265
- to stream Main, to step Curation: 001270
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).</title><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martín">M. Martín</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Chan, A" sort="Chan, A" uniqKey="Chan A" first="A" last="Chan">A. Chan</name><affiliation wicri:level="1"><nlm:affiliation>Curtin University and Breast Cancer Research Centre, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Curtin University and Breast Cancer Research Centre, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Dirix, L" sort="Dirix, L" uniqKey="Dirix L" first="L" last="Dirix">L. Dirix</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncological Research, Sint-Augustinus Hospital, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Oncological Research, Sint-Augustinus Hospital, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="O Shaughnessy, J" sort="O Shaughnessy, J" uniqKey="O Shaughnessy J" first="J" last="O'Shaughnessy">J. O'Shaughnessy</name><affiliation wicri:level="3"><nlm:affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, USA Texas Oncology, US Oncology, Dallas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Baylor-Charles A. Sammons Cancer Center, Dallas, USA Texas Oncology, US Oncology, Dallas</wicri:regionArea><placeName><settlement type="city">Dallas</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Oncologia Clínica, Hospital Pérola Byington and FMUSP, Paulo São, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Centro de Oncologia Clínica, Hospital Pérola Byington and FMUSP, Paulo São</wicri:regionArea><wicri:noRegion>Paulo São</wicri:noRegion></affiliation></author><author><name sortKey="Manikhas, A" sort="Manikhas, A" uniqKey="Manikhas A" first="A" last="Manikhas">A. Manikhas</name><affiliation wicri:level="1"><nlm:affiliation>City Clinical Oncological Dispensary, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>City Clinical Oncological Dispensary, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Shtivelband, M" sort="Shtivelband, M" uniqKey="Shtivelband M" first="M" last="Shtivelband">M. Shtivelband</name><affiliation wicri:level="1"><nlm:affiliation>Hematology and Medical Oncology, Ironwood Cancer and Research Centers, Chandler, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology and Medical Oncology, Ironwood Cancer and Research Centers, Chandler</wicri:regionArea><wicri:noRegion>Chandler</wicri:noRegion></affiliation></author><author><name sortKey="Krivorotko, P" sort="Krivorotko, P" uniqKey="Krivorotko P" first="P" last="Krivorotko">P. Krivorotko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Breast Tumors, Petrov Research Institute of Oncology, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Breast Tumors, Petrov Research Institute of Oncology, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Batista L Pez, N" sort="Batista L Pez, N" uniqKey="Batista L Pez N" first="N" last="Batista L Pez">N. Batista L Pez</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Service, Hospital Universitario de Canarias, Tenerife, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Service, Hospital Universitario de Canarias, Tenerife</wicri:regionArea><wicri:noRegion>Tenerife</wicri:noRegion></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M" last="Campone">M. Campone</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cancérologie de l'Ouest, Nantes René Gauducheau Centrede Recherche en Cancérologie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancérologie de l'Ouest, Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:regionArea><wicri:noRegion>Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:noRegion><wicri:noRegion>Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:noRegion></affiliation></author><author><name sortKey="Ruiz Borrego, M" sort="Ruiz Borrego, M" uniqKey="Ruiz Borrego M" first="M" last="Ruiz Borrego">M. Ruiz Borrego</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Khan, Q J" sort="Khan, Q J" uniqKey="Khan Q" first="Q J" last="Khan">Q J Khan</name><affiliation><nlm:affiliation>University of Kansas Medical Center, University of Kansas, Kansas City.</nlm:affiliation><wicri:noCountry code="subField">Kansas City</wicri:noCountry></affiliation></author><author><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><affiliation wicri:level="1"><nlm:affiliation>Highlands Oncology Group, Fayetteville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Fayetteville</wicri:regionArea><wicri:noRegion>Fayetteville</wicri:noRegion></affiliation></author><author><name sortKey="Ramos Vazquez, M" sort="Ramos Vazquez, M" uniqKey="Ramos Vazquez M" first="M" last="Ramos Vázquez">M. Ramos Vázquez</name><affiliation wicri:level="1"><nlm:affiliation>Centro Oncológico de Galicia, La Coruña, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro Oncológico de Galicia, La Coruña</wicri:regionArea><wicri:noRegion>La Coruña</wicri:noRegion></affiliation></author><author><name sortKey="Urban, P" sort="Urban, P" uniqKey="Urban P" first="P" last="Urban">P. Urban</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Goteti, S" sort="Goteti, S" uniqKey="Goteti S" first="S" last="Goteti">S. Goteti</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Di Tomaso, E" sort="Di Tomaso, E" uniqKey="Di Tomaso E" first="E" last="Di Tomaso">E. Di Tomaso</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Institutes for BioMedical Research, Cambridge, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Institutes for BioMedical Research, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Massacesi, C" sort="Massacesi, C" uniqKey="Massacesi C" first="C" last="Massacesi">C. Massacesi</name><affiliation wicri:level="3"><nlm:affiliation>Novartis Oncology, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Oncology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Delaloge, S" sort="Delaloge, S" uniqKey="Delaloge S" first="S" last="Delaloge">S. Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27803006</idno><idno type="pmid">27803006</idno><idno type="doi">10.1093/annonc/mdw562</idno><idno type="wicri:Area/PubMed/Corpus">001112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001112</idno><idno type="wicri:Area/PubMed/Curation">001109</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001109</idno><idno type="wicri:Area/PubMed/Checkpoint">001109</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001109</idno><idno type="wicri:Area/Ncbi/Merge">003E10</idno><idno type="wicri:Area/Ncbi/Curation">003E10</idno><idno type="wicri:Area/Ncbi/Checkpoint">003E10</idno><idno type="wicri:Area/Main/Merge">001265</idno><idno type="wicri:Area/Main/Curation">001270</idno><idno type="wicri:Area/Main/Exploration">001270</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).</title><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martín">M. Martín</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Chan, A" sort="Chan, A" uniqKey="Chan A" first="A" last="Chan">A. Chan</name><affiliation wicri:level="1"><nlm:affiliation>Curtin University and Breast Cancer Research Centre, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Curtin University and Breast Cancer Research Centre, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Dirix, L" sort="Dirix, L" uniqKey="Dirix L" first="L" last="Dirix">L. Dirix</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncological Research, Sint-Augustinus Hospital, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Oncological Research, Sint-Augustinus Hospital, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="O Shaughnessy, J" sort="O Shaughnessy, J" uniqKey="O Shaughnessy J" first="J" last="O'Shaughnessy">J. O'Shaughnessy</name><affiliation wicri:level="3"><nlm:affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, USA Texas Oncology, US Oncology, Dallas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Baylor-Charles A. Sammons Cancer Center, Dallas, USA Texas Oncology, US Oncology, Dallas</wicri:regionArea><placeName><settlement type="city">Dallas</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Oncologia Clínica, Hospital Pérola Byington and FMUSP, Paulo São, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Centro de Oncologia Clínica, Hospital Pérola Byington and FMUSP, Paulo São</wicri:regionArea><wicri:noRegion>Paulo São</wicri:noRegion></affiliation></author><author><name sortKey="Manikhas, A" sort="Manikhas, A" uniqKey="Manikhas A" first="A" last="Manikhas">A. Manikhas</name><affiliation wicri:level="1"><nlm:affiliation>City Clinical Oncological Dispensary, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>City Clinical Oncological Dispensary, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Shtivelband, M" sort="Shtivelband, M" uniqKey="Shtivelband M" first="M" last="Shtivelband">M. Shtivelband</name><affiliation wicri:level="1"><nlm:affiliation>Hematology and Medical Oncology, Ironwood Cancer and Research Centers, Chandler, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology and Medical Oncology, Ironwood Cancer and Research Centers, Chandler</wicri:regionArea><wicri:noRegion>Chandler</wicri:noRegion></affiliation></author><author><name sortKey="Krivorotko, P" sort="Krivorotko, P" uniqKey="Krivorotko P" first="P" last="Krivorotko">P. Krivorotko</name><affiliation wicri:level="1"><nlm:affiliation>Department of Breast Tumors, Petrov Research Institute of Oncology, Saint Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Breast Tumors, Petrov Research Institute of Oncology, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Batista L Pez, N" sort="Batista L Pez, N" uniqKey="Batista L Pez N" first="N" last="Batista L Pez">N. Batista L Pez</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Service, Hospital Universitario de Canarias, Tenerife, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Service, Hospital Universitario de Canarias, Tenerife</wicri:regionArea><wicri:noRegion>Tenerife</wicri:noRegion></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M" last="Campone">M. Campone</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cancérologie de l'Ouest, Nantes René Gauducheau Centrede Recherche en Cancérologie, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancérologie de l'Ouest, Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:regionArea><wicri:noRegion>Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:noRegion><wicri:noRegion>Nantes René Gauducheau Centrede Recherche en Cancérologie</wicri:noRegion></affiliation></author><author><name sortKey="Ruiz Borrego, M" sort="Ruiz Borrego, M" uniqKey="Ruiz Borrego M" first="M" last="Ruiz Borrego">M. Ruiz Borrego</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Khan, Q J" sort="Khan, Q J" uniqKey="Khan Q" first="Q J" last="Khan">Q J Khan</name><affiliation><nlm:affiliation>University of Kansas Medical Center, University of Kansas, Kansas City.</nlm:affiliation><wicri:noCountry code="subField">Kansas City</wicri:noCountry></affiliation></author><author><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><affiliation wicri:level="1"><nlm:affiliation>Highlands Oncology Group, Fayetteville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Fayetteville</wicri:regionArea><wicri:noRegion>Fayetteville</wicri:noRegion></affiliation></author><author><name sortKey="Ramos Vazquez, M" sort="Ramos Vazquez, M" uniqKey="Ramos Vazquez M" first="M" last="Ramos Vázquez">M. Ramos Vázquez</name><affiliation wicri:level="1"><nlm:affiliation>Centro Oncológico de Galicia, La Coruña, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro Oncológico de Galicia, La Coruña</wicri:regionArea><wicri:noRegion>La Coruña</wicri:noRegion></affiliation></author><author><name sortKey="Urban, P" sort="Urban, P" uniqKey="Urban P" first="P" last="Urban">P. Urban</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Goteti, S" sort="Goteti, S" uniqKey="Goteti S" first="S" last="Goteti">S. Goteti</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Di Tomaso, E" sort="Di Tomaso, E" uniqKey="Di Tomaso E" first="E" last="Di Tomaso">E. Di Tomaso</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Institutes for BioMedical Research, Cambridge, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Institutes for BioMedical Research, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Massacesi, C" sort="Massacesi, C" uniqKey="Massacesi C" first="C" last="Massacesi">C. Massacesi</name><affiliation wicri:level="3"><nlm:affiliation>Novartis Oncology, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Oncology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Delaloge, S" sort="Delaloge, S" uniqKey="Delaloge S" first="S" last="Delaloge">S. Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120) appear synergistic with paclitaxel in preclinical and clinical models.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Brésil</li><li>Espagne</li><li>France</li><li>Russie</li><li>Suisse</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Texas</li><li>Île-de-France</li></region><settlement><li>Dallas</li><li>Madrid</li><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Goteti, S" sort="Goteti, S" uniqKey="Goteti S" first="S" last="Goteti">S. Goteti</name><name sortKey="Khan, Q J" sort="Khan, Q J" uniqKey="Khan Q" first="Q J" last="Khan">Q J Khan</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martín">M. Martín</name></region><name sortKey="Batista L Pez, N" sort="Batista L Pez, N" uniqKey="Batista L Pez N" first="N" last="Batista L Pez">N. Batista L Pez</name><name sortKey="Ramos Vazquez, M" sort="Ramos Vazquez, M" uniqKey="Ramos Vazquez M" first="M" last="Ramos Vázquez">M. Ramos Vázquez</name><name sortKey="Ruiz Borrego, M" sort="Ruiz Borrego, M" uniqKey="Ruiz Borrego M" first="M" last="Ruiz Borrego">M. Ruiz Borrego</name></country><country name="Australie"><noRegion><name sortKey="Chan, A" sort="Chan, A" uniqKey="Chan A" first="A" last="Chan">A. Chan</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Dirix, L" sort="Dirix, L" uniqKey="Dirix L" first="L" last="Dirix">L. Dirix</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="O Shaughnessy, J" sort="O Shaughnessy, J" uniqKey="O Shaughnessy J" first="J" last="O'Shaughnessy">J. O'Shaughnessy</name></region><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><name sortKey="Di Tomaso, E" sort="Di Tomaso, E" uniqKey="Di Tomaso E" first="E" last="Di Tomaso">E. Di Tomaso</name><name sortKey="Shtivelband, M" sort="Shtivelband, M" uniqKey="Shtivelband M" first="M" last="Shtivelband">M. Shtivelband</name></country><country name="Brésil"><noRegion><name sortKey="Hegg, R" sort="Hegg, R" uniqKey="Hegg R" first="R" last="Hegg">R. Hegg</name></noRegion></country><country name="Russie"><noRegion><name sortKey="Manikhas, A" sort="Manikhas, A" uniqKey="Manikhas A" first="A" last="Manikhas">A. Manikhas</name></noRegion><name sortKey="Krivorotko, P" sort="Krivorotko, P" uniqKey="Krivorotko P" first="P" last="Krivorotko">P. Krivorotko</name></country><country name="France"><noRegion><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M" last="Campone">M. Campone</name></noRegion><name sortKey="Delaloge, S" sort="Delaloge, S" uniqKey="Delaloge S" first="S" last="Delaloge">S. Delaloge</name><name sortKey="Massacesi, C" sort="Massacesi, C" uniqKey="Massacesi C" first="C" last="Massacesi">C. Massacesi</name></country><country name="Suisse"><noRegion><name sortKey="Urban, P" sort="Urban, P" uniqKey="Urban P" first="P" last="Urban">P. Urban</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001270 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001270 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27803006
|texte= A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27803006" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |